Showing 2111-2120 of 2319 results for "".
- FDA Approves Yervoy for Adjuvant Treatment for Fully Resected Stage III Melanomahttps://practicaldermatology.com/news/fda-approves-yervoy-for-adjuvant-treatment-for-fully-resected-stage-iii-melanoma/2458829/The FDA approved Bristol-Myers Squibb Company’s Yervoy (ipilimumab) 10 mg/kg for the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1mm who have undergone complete resection including total lymphadenectomy. Th
- Phase 3 Data Show Promius Pharma's DFD-01 Met Primary Endpoints for the Treatment of Moderate Psoriasishttps://practicaldermatology.com/news/phase-3-data-show-promius-pharmas-dfd-01-met-primary-endpoints-for-the-treatment-of-moderate-psoriasis/2458833/Findings from two Phase III studies for Promius Pharma’s investigational psoriasis drug DFD-01 show that the agent achieved the primary endpoint at day 15. The primary endpoint was the proportion of patients achieving treatment success at day 15 for both studies. In addition, both stud
- Imlygic Approved for Melanoma; Available in a Weekhttps://practicaldermatology.com/news/imlygic-approved-for-melanoma-available-in-a-week/2458834/The FDA has approved the Biologics License Application for Amgen’s Imlygic™ (talimogene laherparepvec), a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous and nodal lesions in patients with melanoma recurrent after
- Zwivel and CareCredit Team Uphttps://practicaldermatology.com/news/zwivel-and-carecredit-team-up/2458836/CareCredit, a provider of patient financing, and Zwivel, an online cosmetic consultation platform that enables cosmetic patients and doctors to interact prior to an in-office consultation, signed a marketing agreement enabling consumers to apply for a CareCredit health, wellness, and beauty credi
- Phase 2 Psoriasis Study Shows Positive Results for Boehringer Ingelheim's Investigational Biologichttps://practicaldermatology.com/news/phase-2-psoriasis-study-shows-positive-results-for-boehringer-ingelheims-investigational-biologic/2458837/Results from a Phase II head-to-head psoriasis study show superior efficacy of Boehringer Ingelheim’s investigational biologic compound BI 655066 over ustekinumab. After nine months, 69 percent of patients with moderate-to-severe plaque psoriasis maintained PASI 90 with BI 655066, compared
- SecurityMetrics: HIPAA Report Reveals Healthcare's Shortcomingshttps://practicaldermatology.com/news/hipaa-report-reveals-healthcares-shortcomings/2458840/A significant security disparity exists among healthcare c-suite and IT departments, outlined by the SecurityMetrics HIPAA Security Rule Report. In a survey of c-level, risk officers, and IT managers, a 10-20% gap was revealed between what executives believe is happening in regards to patient dat
- Celgene Announces Results From Ongoing Phase 3 LIBERATE Trial of Otezla for Psoriasishttps://practicaldermatology.com/news/celgene-announces-results-from-ongoing-phase-3-liberate-trial-of-otezla-for-psoriasis/2458838/Results from Celgene Corporation’s ongoing Phase 3 LIBERATE trial evaluating Otezla (apremilast) in patients with moderate to severe plaque psoriasis presented at 24th European Academy of Dermatology and Venereology show that half of psoriasis patients treated with oral Otezla achieved PASI
- Study Demonstrates Duac Significantly Reduces Inflammatory Acne Lesionshttps://practicaldermatology.com/news/study-demonstrates-duac-significantly-reduces-inflammatory-acne-lesions/2458846/Stiefel shared the findings of a head-to-head German study demonstrating that, in patients with mild-to-moderate acne vulgaris, treatment with Duac™ 3% (benzoyl peroxide 3% + clindamycin 1%) led to numerically fewer inflammatory and non-inflammatory lesions from baseline compared to treatme
- Revance Therapeutics Initiates Phase 3 Clinical Trial of Botulinum Toxin Type A Topical Gel for Crow's Feethttps://practicaldermatology.com/news/revance-therapeutics-initiates-phase-3-clinical-trial-of-botulinum-toxin-type-a-topical-gel-for-crows-feet/2458857/Revance Therapeutics, Inc. has commenced dosing patients in the Phase 3 pivotal study to evaluate the safety and efficacy of its RT001 investigational topical drug product candidate for the treatment of lateral canthal lines, or crow’s feet. The Phase 3 trial will evaluate the safety and ef
- Nivolumab Approved in Combination with Ipilimumabhttps://practicaldermatology.com/news/nivolumab-approved-in-combination-with-ipilimumab/2458859/The FDA has granted accelerated approval to nivolumab (Opdivo Injection, Bristol-Myers Squibb Company) in combination with ipilimumab for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma. The clinical trial that supported approval randomized (2:1) 142